510 Kardiac Devices, Inc. is a development-stage company dedicated to providing novel cardiovascular devices through which cardiologists can perform procedures to targeted locations within the structures of the heart. Our intuitive platform provides physicians with an increased level of device control, functionality, and visibility. Our practical business strategy is to pursue technologies for which there is a simple and clear path to approval (510 (k) or simpler) in a growing established market for which reimbursement is already established.
510 Kardiac Devices, Inc. was founded in 2015 by Jaime Sarabia and renowned Structural Heat Cardiologist Dr. D. Scott Lim from the University of Virginia Medical Center.
Altis is a biotechnology research tools company, which has developed a patent-pending stem cell technology that recreates the human intestinal epithelium. Altis’ technology, RepliGut, can produce a layer of human proliferative stem cells and terminally differentiated cells, either of the small or large intestine. Our technology is available in two formats; the first format product produces a planar surface of cells, and our second format forms the tissue to the contours of the intestinal lining, mimicking the crypt’s architecture and polarization. Each kit is available with up to 96 tissue samples for compound screening, microbiome research and disease models during preclinical studies.
Smoking remains the primary preventable cause of death in the United States and throughout the world. 70% of smokers want to quit, and 90% of those who try fail. Assuage Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to helping people stop smoking. As a spin-out from the Torrey Pines Institute for Molecular Studies (TPIMS), our goal is to be the first to develop and commercialize a highly differentiated, first-in-class smoking cessation product that is safer and more effective than current products, and with the potential to prevent relapse. Our pipeline includes potential products that address other important addictions, including the abuse of opioids. A successful exit is possible in 4-5 years.
Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with a dismal survival rate that affects 100,000 people in the USA, with 30 to 40 thousand new individuals diagnosed every year. The market for IPF treatments is projected to increase substantially in value as new treatments are developed, with some figures as high as $3.2 billion by 2025. Currently, the IPF market is largely under-penetrated, with only 2 approved treatments, both of which are palliative, not curative. Our company is developing a rapid and robust method to generate therapeutically beneficial stem cells to alleviate fibrotic manifestation and proliferation.
Camras Vision has developed the Camras Shunt, a patented device that provides personalized pressure control to attain the highest level of efficacy in stopping the progression of glaucoma. The Camras Shunt provides a novel long-term solution that is bundled in a safe and simple surgery.
Camras Vision has mitigated risk for investors by:
1) following a shortened pathway to market approval
2) raising over $2.8M in non-dilutive financing
3) developed a product that tackles the number #1 problem faced by glaucoma patients
The first-in-human trial underway is providing encouraging results.
Cellective BioTherapy is an early stage biotherapeutic development company established in 2015 that is focused on significant unmet medical needs in the cancer, autoimmunity, transplantation, and immunodeficiency markets. Cellective’s unique monoclonal antibody and cellular therapy platforms and proprietary pipeline are focused on irreplaceable aspects of B lymphocyte and regulatory B cell (B10 cell) biology. Cellective has developed monoclonal antibodies that preferentially deplete regulatory B10 cells but not other B cells, which augments immunity for the treatment of cancer and infectious disease. In addition, Cellective’s technologies enable unprecedented and rapid human B10 cell expansion ex vivo, which enables production of personalized cellular therapies for the treatment of diverse and complex inflammatory diseases, where current treatments remain inadequate.
Over 24 million Americans suffer from substance use disorders. With few FDA approved treatments available, and none for cocaine, scientists have developed new approaches that specifically address this unmet need. Due to societal views on addiction, pharmaceutical companies have been reluctant to assess these compounds, causing a strategic shift away from early stage assessment and creating a development gap. With the progression of society recognizing addiction as a brain disease, EncepHeal Therapeutics was designed to bridge this gap by identifying these new approaches, accelerating them through early testing, then out-licensing to a strategic pharmaceutical partner, starting with our first in class treatment for cocaine and methamphetamine addictions.
EMRGE LLC and BRIJJITCO LLC were formed to develop and commercialize BRIJJIT™s, a platform of first in category, FDA Class 1, non-invasive devices that simultaneously close wounds while minimizing scars. The founder is a plastic surgeon with significant academic, industry, and medical device development experience. The companies have an internationally respected advisory board experienced in medical device R&D, manufacturing, finance, sales and marketing. A strong team of engineers, designers, regulatory experts, and original equipment manufacturers has been assembled. EMRGE and BRIJJITCO are Georgia companies headquartered in Atlanta and primary manufacturing will also occur in Georgia.
Glioblastoma (GBM) is the most common primary brain tumor, and one of the deadliest forms of cancer. Standard surgery, chemotherapy, and radiation fail to eliminate infiltrative cancer cells, and median survival remains a dismal ~15 months. Drugs that seek out the disseminated GBM cells behind the blood-brain barrier are needed to prevent the inevitable recurrence in patients. Genetically engineered neural stem cells (NSCs) possess unique intrinsic homing properties enabling them to seek out local and infiltrative micro-metastatic GBM foci deposits. NSCs can deliver cytotoxic agents that reduce GBM xenografts 70-90% and markedly extend survival in tumor-bearing mice.The usefulness of this tumor seeking and destroying capability is not limited to GBM or other brain cancers.
KelaHealth is a software-as-a-service company that provides a learning surgical quality ecosystem in hospitals. We use deep learning to predict surgical complications before they occur, provide a platform for surgeons to evaluate which interventions are most impactful for each patient, and deliver evidence-based interventions to all surgeons in a department or hospital. Our product works seamlessly within a provider’s workflow by integrating into the EHR. We provide value by cost reduction from decreased complications, readmissions, reoperations, and revenue generation through increased patient throughput.
Moonlight Therapeutics Inc. is committed to improving the quality of life for people suffering from food allergies. We are a pre-clinical stage company developing treatments for food allergies, which currently have no approved treatment. The first product we are pursuing is an FDA approved treatment for peanut allergies. This allergen immunotherapy treatment will reduce the sensitivity of an allergic patient to peanuts in order to reduce the chance of an anaphylactic reaction from exposure to the allergen.
NovAb, Inc. is commercializing a new class of monoclonal antibodies (mAbs) based on discovery by our founding scientist, Dr. Max Cooper (Emory), of a novel family of highly diverse, antibody-like proteins, termed variable lymphocyte receptors (VLRs) utilized as antigen receptors by the immune system of jawless vertebrates (lamprey and hagfish). VLRs possess diversity and the capacity for high affinity, specific binding comparable to conventional mammalian immunoglobulin (Ig) antibodies, but with distinctive, more rigid binding site that is entirely contained within a small single polypeptide chain structure. Jawless vertebrates and mammals last shared a common ancestor over 500 million ago and this evolutionary distance, distinctive binding site and single polypeptide structure of VLRs provide novel specificities and functions not accessed with Ig antibodies. We have discovered VLR mAbs that recognize novel tumor targets, engineered these as human Ig Fc fusion proteins to recruit immune effector functions and as human T cell chimeric antigen receptors (CARs), and demonstrated in vitro tumor killing and enhanced survival with a human tumor xenograft in vivo disease model.
OneVax LLC is a pre-clinical stage biotechnology company committed to developing novel and effective therapies for type 1 diabetes and other auto-immune diseases. OneVax has developed a propriety biomaterial vaccine delivery platform consisting of injectable PLGA microparticles loaded with immunomodulatory agents capable of restoring immune tolerance and ultimately curing type 1 diabetes. Non-phagocytosable microparticles, self-assembling hydrogels, or cell-conjugated nanoparticles ensure sustained release of select agents designed to create a tolerogenic microenvironment while phagocytosable microparticles allow for uptake and subsequent tolerogenic presentation of specific antigens by antigen presenting cells. OneVax’s therapy is minimally invasive, requires no cell isolation and storage and, due to its stable composition, has an extended shelf-life, simplifying manufacturing and shipping.
Physcient develops smarter instruments for surgeons. We are combining proprietary insights into the mechanics of tissues with new technologies developed in other industries to develop instruments that are faster, safer, and easier to use.
PNP Therapeutics, Inc. has developed a novel treatment for solid tumors. After extensive testing, the product, Gedeptin R, was accepted for a phase I clinical trial, where positive results, both safety and efficacy, were significant. Based on the trial, Gedeptin-R received Orphan Drug status from the FDA for the treatment of Head and Neck Cancer.
PNP Therapeutics,Inc. has been given guidance from the FDA to complete a trial of 50 patients, using multiple dosing, to confirm the results and, by doing so, the Company will apply for regulatory approval from the FDA.
Symberix is a preclinical-stage company pioneering a new category of medicines that work by selectively eliminating harmful bacterial activity without killing beneficial bacteria. The Company’s lead program is a first-in-class prophylaxis for chemotherapy-induced diarrhea (CID), a common, burdensome and sometimes deadly toxicity of chemotherapy triggered by the actions of a drug-metabolizing enzyme in gut bacteria. There are no FDA-approved products indicated to prevent or treat CID, which has a total addressable global market exceeding $5B. Symberix’s therapeutic approach does not merely address the symptoms of CID, but rather targets the underlying cause. Our approach could be expanded for use to prevent intestinal injuries due to NSAIDs as well as other classes of medications.